ClinicalTrials.gg

Program

zamicastat

Also written as “BIA 5-1058”, “Oral zamicastat” and “400 mg BIA 5-1058”.

Its studies are mostly in Pulmonary Arterial Hypertension · Cardiovascular Diseases · Hypertension, led by Bial - Portela C.

Furthest: phase 2, since Mar 18, 202013 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bial - Portela C130 open or runningphase 2since Mar 18, 2020May 26, 2014none ahead

Also a collaborator on its studies: covance.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 26, 2014First study: phase 1 study in HypertensionFirst studyNCT02151994 · 124 enrolled · Netherlands
  2. Mar 29, 2018Phase 1 study in Cardiovascular DiseasesNCT03489005 · 49 enrolled · United Kingdom
  3. Oct 12, 2018Phase 1 study in Pulmonary Arterial HypertensionNCT03708146 · 157 enrolled · United Kingdom
  4. Mar 18, 2020Phase 2 study in Pulmonary Arterial HypertensionNCT04316143 · 33 enrolled · Austria, Germany, Italy and more
  5. Dec 15, 2020Phase 1 study in Pulmonary Arterial HypertensionNCT04675944 · 20 enrolled · Germany
  6. Jul 28, 20216 phase 1 studies in Pulmonary Arterial HypertensionNCT04991207, NCT04991194, NCT04991181 and 3 more
  7. Jul 17, 2023Phase 2 study in Pulmonary Arterial HypertensionNCT06009185 · 20 enrolled · Austria, Germany, Italy and more
  8. Sep 8, 2025Phase 1 study in Pulmonary Arterial HypertensionNCT07173738 · 44 enrolled · United Kingdom

TargetBeta

DBH →read by rule
“Dopamine beta-hydroxylase inhibitor”ChEMBL 37, by rule

Studies

All 13 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07173738Pulmonary Arterial Hypertension · United Kingdom1CompletedSep 7, 201844
NCT06009185Pulmonary Arterial Hypertension · Austria, Germany, Italy and more2CompletedFeb 17, 202220
NCT04994860Pulmonary Arterial Hypertension · Germany1CompletedJun 7, 201820
NCT04994119Pulmonary Arterial Hypertension · Germany1CompletedMay 23, 201826
NCT04991207Pulmonary Arterial Hypertension · Germany1CompletedMay 14, 201844
NCT04991194Pulmonary Arterial Hypertension1TerminatedDec 30, 201661
NCT04991181Pulmonary Arterial Hypertension · Netherlands1CompletedMay 24, 201715
NCT04991155Pulmonary Arterial Hypertension1CompletedSep 22, 201557
NCT04675944Pulmonary Arterial Hypertension · Germany1CompletedMay 25, 201820
NCT04316143Pulmonary Arterial Hypertension · Austria, Germany, Italy and more2CompletedOct 20, 202133
NCT03708146Pulmonary Arterial Hypertension · United Kingdom1CompletedMar 18, 2019157
NCT03489005Cardiovascular Diseases · United Kingdom1CompletedOct 5, 201849
NCT02151994Hypertension · Netherlands1CompletedJan 2012124

How it is read

Names in the registry

  • “BIA 5-1058”, 10 entries
  • “Oral zamicastat”, 2 entries
  • “400 mg BIA 5-1058”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.